IJSDR
IJSDR
INTERNATIONAL JOURNAL OF SCIENTIFIC DEVELOPMENT AND RESEARCH
International Peer Reviewed & Refereed Journals, Open Access Journal
ISSN Approved Journal No: 2455-2631 | Impact factor: 8.15 | ESTD Year: 2016
open access , Peer-reviewed, and Refereed Journals, Impact factor 8.15

Issue: March 2024

Volume 9 | Issue 3

Impact factor: 8.15

Click Here For more Info

Imp Links for Author
Imp Links for Reviewer
Research Area
Subscribe IJSDR
Visitor Counter

Copyright Infringement Claims
Indexing Partner
Published Paper Details
Paper Title: Safety, tolerability and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy
Authors Name: Kalyani Madhukar Mali , Komal Sanjiv Mahajan
Unique Id: IJSDR2301073
Published In: Volume 8 Issue 1, January-2023
Abstract: Duchenne muscular dystrophy (DMD) is caused by mutations in the DMD gene resulting in the absence of dystrophin. Casimersen is a phosphorodiamidate morpholino oligomer designed to bypass frameshift DMD mutations and produce internally truncated, yet functional, dystrophin protein in patients amenable to exon 45 skipping. Our primary study objective was to evaluate safety and tolerability of casimersen; the secondary objective was to characterize the plasma pharmacokinetics. INRODUCTION: - In DMD, frameshift or nonsense mutations in the DMD gene prevent the production of functional dystrophin, resulting in progressive, life-shortening disease. Management of DMD has involved a multidisciplinary approach to treat symptoms and modify disease progression; however, there is no cure for the disease [4] Antisense therapy using chemically engineered antisense oligonucleotides (ASOs) complementary to specific mRNA is a prominent method for treating neuromuscular disorders like Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA) [5,6]. ASOs can be used for RNA degradation, suppression of translation, or modulation of splicing [ 6]. Standard-of-care therapy for DMD includes the long-term use of glucocorticosteroids [7] One approach that has been investigated in the development of therapies for DMD has been to target restoration of the production of functional dystrophin, including using exon skipping. [4,8,9]. The approval, granted under the US FDA’s Accelerated Approval Program, was based on an observed increase in dystrophin production in skeletal muscle in patients treated with casimersen [10]. Dystrophic muscle is not able to recover enough to overcome this loss, gradually leading to fibrotic remodelling and the replacement of muscle with fat [11] In addition to muscle weakness and loss of ambulation, DMD patients develop respiratory and cardiac weakness, requiring palliative care [12] An increase in dystrophin production is considered reasonably likely to predict clinical benefit; however, clinical benefit, including improved motor function, is yet to be established [13]. Continued approval of casimersen in the treatment of DMD may be contingent on verification of a clinical benefit in confirmatory trials.
Keywords: Casimersen , muscular dystrophyk
Cite Article: "Safety, tolerability and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy", International Journal of Science & Engineering Development Research (www.ijsdr.org), ISSN:2455-2631, Vol.8, Issue 1, page no.445 - 446, January-2023, Available :http://www.ijsdr.org/papers/IJSDR2301073.pdf
Downloads: 000336256
Publication Details: Published Paper ID: IJSDR2301073
Registration ID:203446
Published In: Volume 8 Issue 1, January-2023
DOI (Digital Object Identifier):
Page No: 445 - 446
Publisher: IJSDR | www.ijsdr.org
ISSN Number: 2455-2631

Click Here to Download This Article

Article Preview

Click here for Article Preview







Major Indexing from www.ijsdr.org
Google Scholar ResearcherID Thomson Reuters Mendeley : reference manager Academia.edu
arXiv.org : cornell university library Research Gate CiteSeerX DOAJ : Directory of Open Access Journals
DRJI Index Copernicus International Scribd DocStoc

Track Paper
Important Links
Conference Proposal
ISSN
DOI (A digital object identifier)


Providing A digital object identifier by DOI
How to GET DOI and Hard Copy Related
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Creative Commons License
This material is Open Knowledge
This material is Open Data
This material is Open Content
Social Media
IJSDR

Indexing Partner